Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S. investments in research and manufacturing, according to CNBC. In the company's first-quarter earnings call, Bourla said that a clear, stable trade policy would unlock tremendous domestic spending in research and manufacturing. Pfizer’s full-year guidance remains unchanged but does not account for future tariff impacts. CFO Dave Denton said current guidance includes $150 million in costs from existing tariffs and that the company still expects to reach the upper end of its forecast range.
Category
🗞
NewsTranscript
00:00It's Benzinga bringing Wall Street to Main Street.
00:02Pfizer CEO Albert Borla stated that uncertainty over President Trump's plant pharmaceutical
00:06tariffs is deterring new U.S. investments in research and manufacturing, that according to
00:11CNBC. In the company's first quarter earnings call, Borla said that a clear, stable trade policy
00:17would unlock tremendous domestic spending in research and manufacturing. Pfizer's full-year
00:22guidance remains unchanged, but does not account for future tariff impacts. CFO Dave Denton said
00:28current guidance includes $150 million in costs from existing tariffs that the company still
00:34expects to reach the upper end of its forecast range. For all things money, visit Benzinga.com
00:39slash GSTV.